Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...

Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the ...

An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

Researchers found that the medication sulthiame reduced breathing interruptions and improved oxygen levels overnight in people with moderate to severe sleep apnea. The findings were published recently ...

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

A European clinical trial found that sulthiame, a drug used in the treatment of epilepsy, reduced breathing interruptions.

Families say the groundbreaking medicine is transforming the lives of children with Dravet syndrome.

Quality sleep is critical for people living with epilepsy to avoid triggering seizures. Poor sleep can affect seizures, memory, and more.

A new review examines how ketogenic diets influence the brain’s metabolism to reduce seizures, while also revealing major gaps in clinical research. A new review published in The Lancet Neurology look ...